ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
← catalyst calendarNCT07399665 · readout in 589 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
110estimated
Sites
10
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-25 | actual | When the study began enrolling |
| Primary completion | 2028-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Asthma
Primary outcomes
what the primary-completion date above is the date OF1. Change in endoscopic status of CRSwNP based on NPS
measured time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
2. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22)
measured time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
3. Change in endoscopic status of CRSwNP based on NPS
measured time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
4. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22)
measured time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed